西罗莫司在角膜移植术后的应用进展  

Advances of sirolimus after conreal transplantation

作　　者：王莎莎[1] 刘焰[1] 胡道德[2] 

机构地区：[1]上海交通大学医学院附属第一人民医院眼科,上海200080 [2]上海交通大学医学院附属第一人民医院药剂科,上海200080

出　　处：《中国新药与临床杂志》2013年第3期176-180,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：西罗莫司是一种在角膜移植术后抗排斥反应中具有良好应用前景的新型免疫抑制药,它具有与FK506结合蛋白亲和力高、诱导免疫耐受积极、抑制角膜新生血管增殖有效、不良反应轻微等眼部应用特点。西罗莫司在角膜移植术后的应用逐渐朝着局部、联合、缓释的方向发展,提高西罗莫司眼部生物利用度及应用安全性等仍有待深入研究。Sirolimus, as a new immunosuppressive agent, has been confirmed that good application prospeets of inhibiting immunological rejection of implants following corneal transplantation. There are many ocular application features of sirolimus including that high affinity with FK506 binding proteins, active induction of immune tolerance, effective inhibition of corneal neovascularization, mild adverse reaction, and so on. The development direction of sirolimus after corneal transplantation is topical use, joint use, stained release drugdelivery. For better clinical efficacy of sirolimus, the research of ocular bioavailability and ocular application security is still need to be further improved.

关 键 词：西罗莫司 免疫抑制剂 眼科 角膜移植 

分 类 号：R976[医药卫生—药品]